BioSpace News Archive

MedX Health Corp. announced its results for the three-months ended March 31, 2021, which are also available on SEDAR.

Perimeter Medical Imaging AI, Inc., a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, reported financial results for its first quarter ended March 31, 2021 and provided a corporate update.

Baudax Bio, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 14,028,520 shares of common stock and warrants to purchase up to an aggregate of 14,028,520 shares of common stock at a purchase price of $0.85 per share and accompanying warrant in a registered direct offering.

RhoVac AB, a Swedish cancer immunotherapy company, announces , May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021.

WhiteLab Genomics, specialist in artificial intelligence (AI) dedicated to gene and cell therapies, is entering into a collaboration with ART-TG, Inserm laboratory expert in the preclinical and pharmaceutical development of ex vivo gene therapies.

Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite allergen immunotherapy tablet Actair®.

AIDS Healthcare Foundation, the world’s largest provider of HIV/AIDS care globally, calls on the World Health Assembly and world leaders to do everything necessary to conduct an entirely new and independent investigation into the origins of the novel coronavirus.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that members of its executive management team will participate in the following investor conference

AnHeart Therapeutics Co., Ltd. and Innovent Biologics, Inc. announced an exclusive license agreement for the co-development and commercialization of AnHeart’s lead drug candidate taletrectinib, a next-generation tyrosine kinase inhibitor designed to effectively target ROS1 and NTRK, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.